Fever News and Research

RSS

First Edition: May 22, 2012

Today's headlines include reports about a lawsuit brought by Catholic organizations against the Obama administration's contraception coverage rule and a new recommendation on PSA screening by the U.S. Preventive Services Task Force.

22 May 2012

C. difficile infection on the rise

A study presented by Mayo Clinic researchers during Digestive Disease Week 2012 provides clear evidence that the number of people contracting the hard-to-control and treat bacterial infection Clostridium difficile (C. difficile or C. diff) is increasing, and that the infection is commonly contracted outside of the hospital.

22 May 2012

European study on allergies investigates birch, olive and grass pollens

From Finland to Italy and from Spain to Lithuania, thirteen research institutes from eleven European countries took part in the three-year Hialine study. The coordinator was Professor Dr Jeroen Buters of TUM's Chair of Molecular Allergology and the Center of Allergy & Environment.

22 May 2012

Data from Janssen’s SIMPONI Phase 3 study on ulcerative colitis

New study findings presented today show that subcutaneous induction regimens of the anti-tumor necrosis factor (TNF)-alpha therapy SIMPONI (golimumab) induced clinical response in a majority of patients with moderately to severely active ulcerative colitis (UC) who had previously failed or were intolerant to conventional agents.

22 May 2012

InterMune reaches definitive agreement with Vidara to sell Actimmune

InterMune, Inc. today announced that it has reached a definitive agreement with Vidara Therapeutics International Limited (Vidara) to sell its rights to Actimmune (interferon gamma-1b) in a cash transaction valued at $55 million plus a two-year royalty stream.

22 May 2012

Cobiprostone shows promise against NSAID-induced gastric mucosal injury

Sucampo Pharmaceuticals, Inc. today announced the presentation of preclinical data at Digestive Disease Week 2012, in San Diego, which demonstrates the protective effect of cobiprostone against epithelial barrier dysfunction in models of non-steroidal anti-inflammatory drug (NSAID)-induced gastric mucosal injury.

21 May 2012

New study to find best way to give blood transfusions for severely injured patients

Researchers at The University of Texas Health Science Center at Houston (UTHealth) are launching a new research study to find the best way to give blood transfusions for severely injured patients predicted to require massive blood transfusions upon arrival to the Memorial Hermann-Texas Medical Center emergency department. Bryan Cotton, M.D., of UTHealth is principal investigator for this clinical study.

19 May 2012

Huffington Post series of opinion pieces examines NGO priorities for G8

The Huffington Post is running "a series of blogs by leading NGOs to call attention to a range of issues that should be raised at the G8 summit at Camp David in rural Maryland from May 18-19," according to the news service. The following summarizes some of the posts published this week.

18 May 2012

Food safety tips while barbecuing

Barbecue season has begun and Health Canada would like to remind Canadians of steps they can take to avoid foodborne illness caused by bacteria such as E. coli, Salmonella and Campylobacter.

18 May 2012

Spectrum initiates ZEVALIN and MGd Phase 2 combination study in NHL

Spectrum Pharmaceuticals, a biotechnology company with fully integrated commercial and drug development operations with a primary focus in hematology and oncology, today announced the initiation of a Phase 2 study evaluating ZEVALIN (ibritumomab tiuxetan) Injection for intravenous use + rituximab in combination with motexafin gadolinium (MGd) in patients with rituximab-refractory low-grade or follicular B-cell non-Hodgkin's lymphoma.

18 May 2012

Biologists engineer algae to produce potential candidates for malarial vaccine

Biologists at the University of California, San Diego have succeeded in engineering algae to produce potential candidates for a vaccine that would prevent transmission of the parasite that causes malaria, an achievement that could pave the way for the development of an inexpensive way to protect billions of people from one of the world's most prevalent and debilitating diseases. Initial proof-of-principle experiments suggest that such a vaccine could prevent malaria transmission.

17 May 2012

Pfizer fails to meet primary endpoint in TORISEL Phase 3 study for advanced RCC

Pfizer Inc announced that the Phase 3 INTORSECT (B1771003) study, evaluating TORISEL(temsirolimus) in patients with advanced renal cell carcinoma (RCC) whose disease had progressed on or after SUTENT (sunitinib malate) therapy, did not meet the primary endpoint of prolonging progression free survival (PFS) when compared to sorafenib.

16 May 2012

Biogen Idec announces availability of two new AVONEX dosing innovations for MS

Biogen Idec announced that two new dosing innovations designed to help patients receiving once-a-week AVONEX (interferon beta-1a) for relapsing forms of multiple sclerosis (MS) are now available in U.S. pharmacies.

15 May 2012

New insights into how body's innate immunity is triggered to create effective immune response

Singapore scientists from Bioprocessing Technology Institute (BTI) under the Agency of Science, Technology and Research (A*STAR) have for the first time, identified the molecular 'switch' that directly triggers the body's first line of defence against pathogens, more accurately known as the body's "innate immunity".

11 May 2012

Top-line results from Takeda vedolizumab phase 3 trial on Crohn's disease

Takeda Pharmaceutical Company Limited today announced top-line results from the international, randomized, placebo-controlled, double-blind GEMINI II pivotal phase 3 trial. The trial evaluated vedolizumab in 1,115 patients with moderately to severely active Crohn's disease who have failed at least one conventional therapy, including TNFα antagonists.

11 May 2012

NEJM publishes results from Celgene’s REVLIMID phase III studies on MM

Celgene International Sàrl, a subsidiary of Celgene Corporation, today announced that results from three phase III studies evaluating the use of continuous REVLIMID(lenalidomide) treatment in newly diagnosed multiple myeloma (MM) patients or maintenance treatment with lenalidomide following autologous stem cell transplant were published online in the May 10, 2012 edition of the New England Journal of Medicine.

11 May 2012

Leishmaniasis vaccine trial begins in U.S., India

"A vaccine against one of the most neglected yet fatal tropical diseases is being tested for the first time in a clinical trial in India and the U.S.," IRIN reports. Visceral leishmaniasis (VL), "also called kala-azar or black fever, infects an estimated half million persons or more annually," and "it is found most commonly in India, Nepal, Bangladesh, Brazil and Sudan," the news service notes.

10 May 2012

NCPIE launches three acetaminophen safe use modules

The National Council on Patient Information and Education (NCPIE) today launched three customized, online educational modules to promote safe use of acetaminophen products.

8 May 2012

Dengue fever costs Puerto Rico nearly $38M a year, study shows

"The costs of treating and coping with dengue fever in Puerto Rico total nearly $38 million a year, a new study," published Wednesday in the American Journal of Tropical Medicine and Hygiene, finds, according to U.S. News & World Report.

5 May 2012

GenVec receives NIAID’s Phase I SBIR grant to support RSV vaccine program

GenVec, Inc. announced today that it has received a Phase I Small Business Innovation and Research (SBIR) grant from the National Institute of Allergy and Infectious Diseases (NIAID) of the National Institutes of Health (NIH) to support the Company's Respiratory Syncytial Virus (RSV) vaccine program.

4 May 2012